Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 53 of 53 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/16
End: 08/31/17
Due: 08/31/18
Phase: N/A
Priority: Normal
Start: 10/24/23
End: 12/11/24
Due: 12/11/25
Phase: N/A
Priority: Normal
Start: 12/31/10
End: 02/28/13
Due: 02/28/14
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema | NCT02870972 | BioCryst Pharmaceuticals | user2@example.com | None | 2016-08-31 | 2017-08-31 | 2018-08-31 | - | - | 2025-07-14 |
| Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) | NCT06100900 | BioCryst Pharmaceuticals | user2@example.com | None | 2023-10-24 | 2024-12-11 | 2025-12-11 | - | - | 2025-07-14 |
| Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol | NCT01265264 | BioCryst Pharmaceuticals | user2@example.com | None | 2010-12-31 | 2013-02-28 | 2014-02-28 | - | - | 2025-07-14 |